“…Nodal graph measures characterize individual node properties and the influence of the nodes on the network (Rubinov & Sporns, 2010). Many of these measures have been shown to reflect disease-related abnormalities in the brain networks of patients with epilepsy (Garcia-Ramos, Song, Hermann, & Prabhakaran, 2016;Pourmotabbed, Wheless, & Babajani-Feremi, 2020;Quraan, McCormick, Cohn, Valiante, & McAndrews, 2013), Alzheimer's disease (Hojjati, Ebrahimzadeh, & Babajani-Feremi, 2019;Khazaee, Ebrahimzadeh, & Babajani-Feremi, 2015;Stam et al, 2009), schizophrenia (Hadley et al, 2016;Jalili & Knyazeva, 2011), autism (Tsiaras et al, 2011;Zeng et al, 2017), or other disorders. This suggests that graph measures have the potential to be useful as clinical biomarkers.…”